XXI Conference of the Graduate Committee of the Argentine Diabetes Society. Artificial intelligence and new technologies: transformation of the digital ecosystem in the care of patients with diabetes

Authors

  • Carolina Figueredo San Ramón Clinic, Chaco, Argentina
  • Luis Biliato Public Employees' Health Plan of Mendoza, Mendoza, Argentina
  • Laura Dimov Lencinas Hospital, Mendoza, Argentina
  • Susana Beatriz Apoloni Austral University Hospital, Pilar, Buenos Aires Province, Argentina
  • Bárbara Arinovich Private practice, City of Buenos Aires, Argentina
  • Roberto Aiziczon Avellaneda Hospital, Tucumán, Argentina
  • Viviana Sosa Dr. Ramón Madariaga Acute Care Teaching Hospital, Posadas, Misiones, Argentina
  • Enrique Majul Medical Council of Córdoba, Córdoba, Argentina

DOI:

https://doi.org/10.47196/diab.v60i2.1362

Keywords:

artificial intelligence, machine learning, deep learning, continuous glucose monitoring, automated insulin dosing, smart pens, platforms, telemedicine

Abstract

Introduction: traditional models for caring for patients with diabetes show structural limitations in the face of the sustained growth of healthcare demand. Artificial intelligence emerges here as a tool with real transformative capacity. It can process large amounts of clinical data, recognize patterns that escape conventional analysis, and suggest personalized recommendations, opening concrete possibilities to improve both patient outcomes and the efficiency of the healthcare system.

Materials and methods: a descriptive bibliographic search was conducted, focusing on: clinical practice guidelines, meta-analyses, systematic reviews, and controlled trials. Publications from the last five years were prioritized, and when it was necessary to support essential concepts, earlier sources were consulted. Focused on the applications of artificial intelligence that facilitate the physician's work in the daily management of diabetes.

Results: machine learning and deep learning systems have improved the functioning of automated insulin pumps, achieving more precise metabolic control. Evidence shows that artificial intelligence contributes to the early diagnosis of type 1, type 2, and gestational diabetes. It also helps predict chronic complications and personalize treatments. Continuous glucose monitors, smart insulin pens, data download platforms, and telemedicine are tools that help integrate all this information and maintain effective contact with the patient.

Conclusions: artificial intelligence in the field of diabetes is advancing rapidly. Professionals working in this area need to stay updated, adapting recommendations to each case, educating patients, and promoting equitable access to these technologies. But individualization remains the main priority: it is necessary to choose for each patient according to their particular characteristics.

Author Biographies

Carolina Figueredo, San Ramón Clinic, Chaco, Argentina

Board-certified specialist in Internal Medicine, specializing in Diabetes (Argentine Diabetes Society), self-employed practitioner

Luis Biliato, Public Employees' Health Plan of Mendoza, Mendoza, Argentina

Family Physician specializing in Diabetes (Argentine Diabetes Society). Faculty member at the National University of Cuyo, Director of the Internal Medicine rotation, Vice President of CEIS-OSEP

Laura Dimov, Lencinas Hospital, Mendoza, Argentina

Physician specializing in Internal Medicine and Diabetes (Argentine Diabetes Society); Secretary of the Graduates' Committee, Argentine Diabetes Society

Susana Beatriz Apoloni, Austral University Hospital, Pilar, Buenos Aires Province, Argentina

Master in Diabetes; physician specializing in Internal Medicine and Nutrition, with a specialization in Diabetes (Argentine Diabetes Society); staff member of the Diabetes Service

Bárbara Arinovich, Private practice, City of Buenos Aires, Argentina

Physician specializing in Internal Medicine, Nutrition, and Diabetes (University of Buenos Aires, UBA); Full Member of the Argentine Diabetes Society

Roberto Aiziczon, Avellaneda Hospital, Tucumán, Argentina

General Practitioner, University Specialist in Nutrition, specializing in Diabetes (Argentine Diabetes Society), Staff Physician in the Endocrinology and Diabetes Department

Viviana Sosa, Dr. Ramón Madariaga Acute Care Teaching Hospital, Posadas, Misiones, Argentina

Physician specializing in Internal Medicine and Diabetes (Argentine Diabetes Society)

Enrique Majul, Medical Council of Córdoba, Córdoba, Argentina

Doctor of Medicine, specialist in Internal Medicine, Director of the Master's Program in Diabetology and Nutrition at the Catholic University of Córdoba, General Director of the Reina Fabiola University Clinic, and diabetes expert

References

I. Rani KMJ. Diabetes prediction using machine learning. Int J Sci Res Comp Sci Eng Inf Tech. 2020;6(4):295-305.

II. Ellahham S. Artificial intelligence: the future for diabetes care. Am J Med. 2020;133(8):895-900.

III. Corrao S, Janić M, Maggio V, Rizzo M. Machine learning and deep learning in diabetology. Front Clin Diabetes Healthc. 2025;6:1547689.

IV. Beneyto A, Contreras I, Vehi Y. Inteligencia artificial y diabetes. Rev Soc Esp Diabetes. 2023.

V. Enes-Romero P, Güemes M, Guijo B, Martos-Moreno GÁ, et al.. Automated insulin delivery systems in the treatment of diabetes. Endocrinol Diabetes Nutr. 2024;71(10):436-46.

VI. Phillip M, Nimri R, Bergenstal RM, Barnard-Kelly, et al. Consensus recommendations for the use of automated insulin delivery technologies. Endocr Rev. 2023;44(2):254-80.

VII. Boughton CK, Hovorka R. New closed-loop insulin systems. Diabetologia. 2021;64(5):1007-15.

VIII. Víbora PIB, Férnandez K, Carril NA, Curieses NP. Guía de uso de sistemas de asa cerrada 2025. Grupo GTTAD-SED; 2025. Disponible en: https://www.sediabetes.org/wp-content/uploads/GTTAD_GUIA_SAC_2025_vF.pdf.

IX. Kadiyala N, Hovorka R, Boughton CK. Closed-loop systems: recent advancements. Expert Rev Med Devices. 2024;21(10):927-41.

X. Boughton CK, Hovorka R. The role of automated insulin delivery technology in diabetes. Diabetologia. 2024;67(10):2034-44.

XI. Guan Z, Li H, Liu R, Cai C, et al. Artificial intelligence in diabetes management. Cell Rep Med. 2023;4(10):101213.

XII. Kiran M, Xie Y, Anjum N, Ball G, et al. Machine learning and AI in type 2 diabetes prediction. Front Digit Health. 2025;7:1557467.

XIII. Khokhar PB, Gravino C, Palomba F. Advances in AI for diabetes prediction. Artif Intell Med. 2025;164:103132.

XIV. Mittal R, Weiss MB, Rendon A, Shafazand S, et al. Machine learning for early detection of type 1 diabetes. Int J Mol Sci. 2025;26(9):3935.

XV. AlSaad R, Elhenidy A, Tabassum A, Odeh N, et al. Artificial intelligence in gestational diabetes care. J Diabetes Sci Technol. 2025.

XVI. Sobhi N, Sadeghi-Bazargani Y, Mirzaei M, Abdollahi M, et al. AI for early detection of diabetes mellitus complications. J Diabetes Metab Disord. 2025;24(1):104.

XVII. Yang Q, Bee YM, Lim CC, Sabanayagam C, et al. Use of AI with retinal imaging in screening for diabetes-associated complications. EClinicalMedicine. 2025;81:103089.

XVIII. Dai C, Sun X, Xu J, Chen M, et al. Machine learning in prediction of diabetic kidney Disease. Int J Med Inform. 2025;202:105975.

XIX. Nur A, Tjandra S, Yunnanisha DA, Keane A, et al. Predicting cardiovascular risks in type 2 diabetes with AI. Narra J. 2025;5(1):e2116.

XX. Davis GM, Peters AL, Bode BW, Carlson AL, et al. Glycaemic outcomes with Omnipod 5 in type 2 diabetes. Diabetes Obes Metab. 2025;27(1):143-54.

XXI. Sen A, Mohanraj PS, Laxmi V, Ashique S, et al. AI-based treatment strategy in type 2 diabetes. J Pharm Anal. 2025;15(6):101305.

XXII. Rosenbacke R, Melhus A, Mckee M, Stuckler D. Explainable AI in health care. JMIR AI. 2024;3:e53207.

XXIII. Gala KM. Ethical and legal considerations in AI-driven health. Int J Sci Res Comp Sci Eng Inf Tech. 2024;10(5):682-90.

XXIV. American Diabetes Association. Diabetes Technology: Standards of Care 2025. Diabetes Care. 2024;48(Suppl 1):S146-66.

XXV. Yoo JH, Kim JH. Advances in continuous glucose monitoring. Diabetes Metab J. 2023;47(1):27-41.

XXVI. Kwon SY, Moon JS. Advances in CGM: clinical applications. Endocrinol Metab. 2025;40(2):161-73.

XXVII. Fishman S, editor. Advances in diabetes technology. Cham (CH): Springer; 2025. (Contemporary Endocrinology). doi:10.1007/978-3-031-75352-7.

XXVIII. Bender C,Vestergaad O, Cichosz SL. The history, evolution and future of CGM. Diabetology. 2025;6(3):17. doi: 10.3390/diabetology6030017

XXIX. Kong YW, Morrison D, Lu JC, Lee MH, et al. Continuous ketone monitoring. Diabetes Obes Metab. 2024;26(Suppl 7):47-58.

XXX. Battelino T, Danne T, Bergenstal RM, Amiel SA, et al. Clinical Targets for CGM Data Interpretation. Diabetes Care. 2019;42(8):1593-603.

XXXI. American Diabetes Association. Diabetes Technology: Standards of Care 2026. Diabetes Care. 2025;49(Suppl 1):S150-65.

XXXII. Boonpattharatthiti K, Saensook T, Neelapaijit N, Sakunrag I, et al. Adherence to insulin therapy. Res Social Adm Pharm. 2024;20(3):255-95.

XXXIII. Lingen K, Pikounis T, Bellini N, Isaacs D, et al. Connected insulin pens in diabetes management. Endocr Connect. 2023;12(11):e230108.

XXXIV. Tejera-Pérez C, Chico A, Azriel-Mira S, Lardiés-Sánchez B, et al. Connected insulin pens: expert recommendation. Diabetes Ther. 2023;14(7):1077-91.

XXXV. Ramírez-Mendoza F, González JE, Gasca E, Camacho M, et al. Time in range with multidisciplinary program in pediatric diabetes. Pediatr Diabetes. 2020;21(1):61-68.

XXXVI. Sy SL, Munshi MM, Toschi E. Can smart pens help improve diabetes management? J Diabetes Sci Technol. 2022;16(3):628-34.

XXXVII. Adolfsson P, Björnsson V, Hartvig NV, Kaas A, et al. Improved glycemic control with smart insulin pens. Diabetes Ther. 2022;13(1):43-56.

XXXVIII. MacLeod J, Vigersky RA. Precision insulin management with smart insulin pens. J Diabetes Sci Technol. 2023;17(2):283-9.

XXXIX. Mackenzie SC, Sainsbury CAR, Wake DJ. Diabetes and AI beyond the closed loop. Diabetologia. 2024;67(2):223-35.

XL. Arbiter B, Look H, McComb L, Snider C. Why download data: benefits and challenges. Diabetes Spectr. 2019;32(3):221-5.

XLI. Akturk HK, Bindal A. Advances in diabetes technology within the digital ecosystem. J Manag Care Spec Pharm. 2024;30(10-b Suppl):S7-20.

XLII. Sociedad Española de Diabetes. Manual de telemedicina y diabetes. Disponible en: www.sediabetes.org.

XLIII. Wong JC, Izadi Z, Schroeder S, Nader M, et al. Software platform for diabetes device data. Diabetes Technol Ther. 2018;20(12):806-16.

XLIV. Eberle C, Stichling S, Löhnert M. Diabetology 4.0: Digitalization insights. J Med Internet Res. 2021;23(3):e23475.

XLV. Dhediya R, Chadha M, Bhattacharya AD, Godbole S, et al. Role of telemedicine in diabetes management. J Diabetes Sci Technol. 2023;17(3):775-81.

XLVI. Verhoeven F, Van Gemert-Pijnen L, Dijkstra K, Nijland N, et al. Teleconsultation and videoconferencing in diabetes care. J Med Internet Res. 2007;9(5):e37.

XLVII. Marcolino MS, Oliveira JAQ, D’Agostino M, Ribeiro AL, et al. Impact of mHealth Interventions. JMIR Mhealth Uhealth. 2018;6(1):e23.

XLVIII. Zhang K, Huang Q, Wang Q, Li C, et al. Telemedicine in glycemic control in children with T1DM. J Med Internet Res. 2024;26:e51538.

XLIX. Hangaard S, Laursen SH, Andersen JD, Kronborg T, et al. Effectiveness of telemedicine for type 2 diabetes. J Diabetes Sci Technol. 2023;17(3):794-825.

L. Dat TV, Binh V, Hoang TM, Tu VL, et al. Effectiveness of telemedicine in type 2 diabetes. Sage Open Medicine. 2024;12.

LI. Laursen SH, Boel L, Udsen FW, Secher PH, et al. Telemedicine in managing diabetes in pregnancy. J Diabetes Sci Technol. 2023;17(5):1364-75.

LII. Suhlrie L, Ayyagari R, Mba C, Olsson K, et al. Telemedicine in prevention of type 2 diabetes. Diabetes Metab Syndr. 2025;19(5):103252.

LIII. Pérez K, Wisniewski D, Ari A, Lee K, et al. Investigation into application of AI and telemedicine in rural communities. A systematic literature review. Healthcare (Basel). 2025 Feb 4;13(3):324. doi: 10.3390/healthcare13030324. PMID: 39942513; PMCID: PMC11816903.

LIV. Montero-Delgado JA, Merino Alonso FJ, Monte Boquet E, Ávila de Tomásc JF, et al. Competencias digitales de profesionales sanitarios. Educ Med. 2019;21(5):338-44. doi: 10.1016/j.edumed.2019.02.010

LV. Puchades R, Ramos-Ruperto L, en nombre del Grupo de Trabajo de Medicina Digital de la SEMI. Artificial intelligence in clinical practice. Rev Clin Esp. 2025;225(1):23-7.

Downloads

Published

2026-07-29

Issue

Vol. 60 No. 2 (2026): May–August

Section

Conferences

License

Copyright (c) 2026 on behalf of the authors. Reproduction rights: Argentine Diabetes Society

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.

La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.

Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.